PFE logo Pfizer +
Pfizer
+

Pfizer (PFE) Business News

Track Pfizer in real time with a live news feed covering Pfizer stock news, official press releases, company announcements, and an archive of historical Pfizer news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
5:15 PM | Monday | May 25, 2026 The Motley Fool

This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?

News Thumbnail
1:26 PM | Monday | May 25, 2026 Zacks Investment Research

MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

News Thumbnail
8:30 AM | Monday | May 25, 2026 Seeking Alpha

Dividend Harvesting Portfolio Week 273: $27,300 Allocated, $3,021.95 In Projected Dividends

News Thumbnail
5:45 AM | Monday | May 25, 2026 Fool - Investing News

Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

News Thumbnail
8:30 AM | Monday | May 25, 2026 Seeking Alpha

Dividend Harvesting Portfolio Week 273: $27,300 Allocated, $3,021.95 In Projected Dividends

News Thumbnail
5:45 AM | Monday | May 25, 2026 Fool - Investing News

Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

News Thumbnail
12:00 PM | Sunday | May 24, 2026 The Motley Fool

What's the Better Dividend Stock Today: AbbVie or Pfizer?

News Thumbnail
11:05 AM | Friday | May 22, 2026 Zacks Investment Research

J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

News Thumbnail
10:01 AM | Friday | May 22, 2026 Zacks Investment Research

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

News Thumbnail
7:19 AM | Friday | May 22, 2026 Seeking Alpha

Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy

News Thumbnail
12:54 PM | Wednesday | May 20, 2026 Seeking Alpha

FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer

News Thumbnail
11:46 AM | Wednesday | May 20, 2026 Zacks Investment Research

Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion

News Thumbnail
9:00 AM | Wednesday | May 20, 2026 Business Wire

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

News Thumbnail
5:08 AM | Wednesday | May 20, 2026 Reuters

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

News Thumbnail

This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?

The Motley Fool

5:15 PM | Monday | May 25, 2026

news photo
Loading...

Pfizer is offering investors a huge 6.6% dividend yield. The pharmaceutical giant isn't hitting on all cylinders, but dividend investors shouldn't abandon the company yet.

Read full article redirect
5:15 PM | Monday | May 25, 2026

This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?

The Motley Fool

Pfizer is offering investors a huge 6.6% dividend yield. The pharmaceutical giant isn't hitting on all cylinders, but dividend investors shouldn't abandon the company yet.

Read full article arrow
News Thumbnail
1:26 PM | Monday | May 25, 2026

MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

Zacks Investment Research

Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.

Read full article arrow
News Thumbnail
8:30 AM | Monday | May 25, 2026

Dividend Harvesting Portfolio Week 273: $27,300 Allocated, $3,021.95 In Projected Dividends

Seeking Alpha

The Dividend Harvesting Portfolio reached a record $39,166.48, up 43.47% on invested capital, with forward annualized dividend income surpassing $3,000. My disciplined, diversified approach—capping positions at 5% and sectors at 20%—enables risk mitigation and robust, recurring income growth. Recent additions include AGNC (13.
4% yield, strong dividend coverage) and Pfizer (6.5% yield, reaffirmed bullish 2026 guidance), positioning for a potential lower-rate environment.

Read full article arrow
News Thumbnail
5:45 AM | Monday | May 25, 2026

Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

Fool - Investing News

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

Read full article arrow
News Thumbnail
8:30 AM | Monday | May 25, 2026

Dividend Harvesting Portfolio Week 273: $27,300 Allocated, $3,021.95 In Projected Dividends

Seeking Alpha

The Dividend Harvesting Portfolio reached a record $39,166.48, up 43.47% on invested capital, with forward annualized dividend income surpassing $3,000. My disciplined, diversified approach—capping positions at 5% and sectors at 20%—enables risk mitigation and robust, recurring income growth. Recent additions include AGNC (13.
4% yield, strong dividend coverage) and Pfizer (6.5% yield, reaffirmed bullish 2026 guidance), positioning for a potential lower-rate environment.

Read full article arrow
News Thumbnail
5:45 AM | Monday | May 25, 2026

Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

Fool - Investing News

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

Read full article arrow
News Thumbnail
12:00 PM | Sunday | May 24, 2026

What's the Better Dividend Stock Today: AbbVie or Pfizer?

The Motley Fool

Pfizer's dividend yield is far higher than AbbVie's, but the key issue is whether the payout is safe. AbbVie has been a dividend growth beast for several years, and that trend could very well continue.

Read full article arrow
News Thumbnail
11:05 AM | Friday | May 22, 2026

J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

Zacks Investment Research

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

Read full article arrow
News Thumbnail
10:01 AM | Friday | May 22, 2026

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Zacks Investment Research

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read full article arrow
News Thumbnail
7:19 AM | Friday | May 22, 2026

Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy

Seeking Alpha

PFE's aggressive M&A and in-house R&D efforts are paying off, with the growth portfolio (newly launched/acquired products) already delivering $3.1B in revenues in FQ1'26 (+22% YoY operationally). LOE risks are mitigated by delayed Vyndamax generic entry to mid-2031, supporting the management's high single-digit 5Y revenue growth guidance from 2029 onwards. PFE's intermediate-term performance is expected to remain lumpy, but the cost saving efforts, strong interest coverage, and dividend sustainability underpin its compelling investment thesis.

Read full article arrow
News Thumbnail
12:54 PM | Wednesday | May 20, 2026

FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer

Seeking Alpha

Johnson & Johnson offers a superior return/risk profile versus Pfizer, driven by consistency and operational stability. PFE's far lower valuation (FWD P/E 8.55x, PEGY 0.97x) and far higher yield (6.79%) are certainly attractive.
But JNJ's 63-year streak of dividend growth, lower payout ratio (48.46%), ongoing buybacks, and stable inventory all point to far superior consistency.

Read full article arrow
News Thumbnail
11:46 AM | Wednesday | May 20, 2026

Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion

Zacks Investment Research

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 20, 2026

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer's oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home. Central to the collaboration is SCRI's Accelero™, a next-generation clinic.

Read full article arrow
News Thumbnail
5:08 AM | Wednesday | May 20, 2026

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Reuters

Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up ​to 15-fold higher antibody levels against a key strain, ‌in a mid-stage study.

Read full article arrow
News Thumbnail